This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-15 and is reviewed periodically as new material appears.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Narrated by Henrietta Bess, produced by Nicholas Kent, directed by Peter Webber 19 July What Shall We Do with the Moon?, shown thirty years after the 1969 Moon landing; about colonization of the Moon; Greg Bennett (writer); the Apollo 17 mission, in December 1972; Alan Binder, who worked on the January 1998 Lunar Prospector, which discovered water on the Moon; Jim Benson and his SpaceDev at Poway, California; the Thunderbird proposal of Starchaser Industries; the Nomad rover, developed by Carnegie Mellon University in Pittsburgh; chemist Nigel Packham of NASA; physicist David Criswell, and solar power on the Moon. Narrated by Scottish actress Daniela Nardini, produced by Katrina Phillips, directed by Chris Durlacher, made by Wall to Wall Television. Shown on the Discovery Science (European TV channel) 6 September Frozen Hearts, up to 50% of people on a heart-lung machine have some form of brain deterioration, and for one in five, the deterioration is permanent Alan Egar had heart surgery, but he had memory difficulties after the operation; he found difficulty finishing sentences; in the US four-year-old Samantha Summers is put on a heart-lung machine at Boston Children's Hospital; David Eckmann, later the Horatio C.
== Personalized Medicine == As metabolite analyses are being conducted at the individual patient level, pharmacometabolomics may be considered a form of personalized medicine. This field is currently being employed in a predictive manner to determine the potential responses of therapeutic compounds in individual patients, allowing for more customized treatment regimens. It is anticipated that such pharmacometabolomics approaches will lead to the improved ability to predict an individual's response to a compound, the efficacy and metabolism of it as well as adverse or off-target effects that may take place in the body. The metabolism of certain drugs varies from patient to patient as the copy number of the genes which code for common drug metabolizing enzymes varies within the population, and leads to differences in the ability of an individual to metabolize different compounds. Other important personal factors contributing to an individual's metabolic profile, such as patient nutritional status, commensal bacteria, age, and pre-existing medical conditions, are also reflected in metabolite assessment., Overall, pharmacometabolomic analyses combined with such approaches as pharmacogenetics, can function to identify the metabolic processes and particular genetic alterations that may compromise the anticipated efficacy of a drug in a particular patient. The results of such analyses can then allow modification of treatment regimens for an optimal outcome.
== Pharmacodynamics == CPA has antiandrogenic activity, progestogenic activity, weak partial glucocorticoid activity, weak steroidogenesis inhibitor activity, and agonist activity at the pregnane X receptor. It has no estrogenic or antimineralocorticoid activity. In terms of potency, CPA is described as a highly potent progestogen, a moderately potent antiandrogen, and a weak glucocorticoid.
Thomas A. Wadden (born September 3, 1952) is an American psychologist who is known for his research on the behavioral, pharmacological, and surgical treatment of obesity. He is Professor of Psychology in Psychiatry at the Perelman School of Medicine at the University of Pennsylvania, where he served as Director of the Center for Weight and Eating Disorders for over two decades. From 2011 to 2021, he held the endowed Albert J. Stunkard Professorship in Psychiatry. Wadden has published more than 500 peer-reviewed scientific papers and edited seven volumes on obesity and eating disorders. He has contributed to national health policy on obesity management, serving on expert panels for the National Institutes of Health, the Federal Trade Commission, the Department of Veterans Affairs, and the United States House of Representatives. He is a fellow of The Obesity Society. In 2015, The Obesity Society created the Thomas A. Wadden Award for Distinguished Mentorship, recognizing his education of scientists and practitioners in the field of obesity.
Sources: en.wikipedia.org
=== First modular space station === The USSR turned its space program to the development of the low Earth orbit modular space station Mir (peace or world) assembled in orbit from 1986 to 1996. At 129,700 kilograms (285,900 lb), it held records for the largest spacecraft and the longest continuous human presence in space at 3,644 days, until the International Space Station was built starting in 1998. Mir's operation continued after the 1991 replacement of the USSR's space program with the Russian Federal Space Agency until 2001, supported by Soyuz spacecraft.
However, Karachi-based K-Electric and Water and Power Development Authority (WAPDA) generate much of the electricity used in Pakistan and collect revenue nationwide. In 2023, Pakistan's installed electricity generation capacity was ~45,885 MWt. Pakistan produced 1,135 megawatts of renewable energy for the month of October 2016. Pakistan expects to produce 10,000 megawatts of renewable energy by 2025.
In Iceland, flunitrazepam is a controlled substance available from Mylan. It is prescribed for severe insomnia and is sometimes used before surgery to induce a calm, relaxed state of mind for the patient. In Sweden, flunitrazepam is a List II drug (substances with medicinal uses) under the Narcotics Control Act (1968). It was previously available from Mylan, but has been removed from the market in January 2020. In the United Kingdom, flunitrazepam is not licensed for medical use and is a controlled drug under Schedule 3 and Class C. In the United States, the drug has not been approved by the Food and Drug Administration and is considered to be an illegal drug; as of 2016 it is Schedule IV. 21 U.S.C. § 841 and 21 U.S.C. § 952 provide for punishment for the importation and distribution of up to 20 years in prison and a fine; possession is punishable by three years and a fine. Travelers travelling into the United States are limited to a 30-day supply. The drug must be declared to US Customs upon arrival. If a valid prescription cannot be produced, the drug may be subject to Customs search and seizure, and the traveler may face criminal charges or deportation.
==== Coupling with separation techniques ==== DART can be combined with many separation techniques. Thin-layer chromatography (TLC) plates have been analyzed by positioning them directly in the DART gas stream. Gas chromatography has been carried out by coupling gas chromatography columns directly into the DART gas stream through a heated interface. Eluate from a high-pressure liquid chromatograph (HPLC) can be also introduced to the reaction zone of the DART source and analyze. DART can be coupled with capillary electrophoresis (CE) and the eluate of CE is guided to the mass spectrometer through the DART ion source.
== Clinical trials == In June 2020, CureVac was launched for phase I trial with 280 participants. In August, CureVac was launched for phase II trials with 674 participants. In November, CureVac reported results of a Phase I-II clinical trial that CVnCoV (active ingredient zorecimeran) was well-tolerated, safe, and produced a robust immune response. In December 2020, CureVac began a Phase III clinical trial of CVnCoV with 36,500 participants. Bayer will provide clinical trial support and international logistics for the Phase III trial, and may be involved in eventual manufacturing should the vaccine prove to be safe and effective. In February 2021, the EU's CHMP started a rolling review of CVnCoV. In April 2021, the same procedure began in Switzerland. In June 2021, CureVac announced that the vaccine's efficacy against symptomatic disease is 48%. The company said the high number of variants in circulation may explain the low efficacy, but some scientists attribute the result to insufficient immunogenicity due to the use of unmodified mRNA (the Pfizer–BioNTech and Moderna vaccines use uracil-modified mRNA) or the dose being too low (12 μg, compared to 30 μg for Pfizer–BioNTech and 100 μg for Moderna). Neutralizing antibody levels in CureVac recipients were about the same as those in convalescence, but much lower than those seen in recipients of Pfizer–BioNTech or Moderna. The modified mRNA induces potent antibodies and other protective immune responses and circumvents the body's inflammatory reactions.
Sources: en.wikipedia.org
India accounts for the bulk of the Indian subcontinent, lying atop the Indian tectonic plate, a part of the Indo-Australian Plate. India's defining geologic processes began approximately 70 million years ago, when the Indian Plate, then part of the southern supercontinent Gondwana, began a north-eastward drift caused by seafloor spreading to its south-west, and later, south and south-east. Simultaneously, the vast Tethyan oceanic crust, to its northeast, began to subduct under the Eurasian Plate. The Indian continental crust was obstructed and was sheared horizontally; while its lower crust and mantle slid beneath Eurasia, the upper layer piled up in sheets ahead of the subduction zone. This mountain-building orogeny created the Himalayas. The middle and stiffer layer continued to push into Tibet, causing crustal thickening of the Tibetan Plateau. Immediately south of the emerging Himalayas, plate movement created a vast crescent-shaped trough that rapidly filled with river-borne sediment and now constitutes the Indo-Gangetic Plain. The original Indian plate makes its first appearance above the sediment in the ancient Aravalli range, which extends from the Delhi Ridge in a southwesterly direction. To the west lies the Thar Desert, whose eastern spread is checked by the Aravallis.
What are the basic building blocks of emotional life? Why is it that people quickly and effortlessly perceive anger, sadness, fear in themselves and others, yet scientists have been unable to specify a set of clear criteria for empirically identifying these emotional events? What roles do language and conceptual knowledge play in emotion perception Are there really differences between the emotional lives of men and women (see Sex differences in psychology § Emotion)
Amino acids are polymerised via peptide bonds to form a long backbone, with the different amino acid side chains protruding along it. In biological systems, proteins are produced during translation by a cell's ribosomes. Some organisms can also make short peptides by non-ribosomal peptide synthesis, which often use amino acids other than the encoded 22, and may be cyclised, modified and cross-linked.
== Disadvantages == The Bradford assay is linear over a short range, typically from 0 μg/mL to 2000 μg/mL, often making dilutions of a sample necessary before analysis. In making these dilutions, error in one dilution is compounded in further dilutions resulting in a linear relationship that may not always be accurate. Basic conditions and detergents, such as SDS, can interfere with the dye's ability to bind to the protein through its side chains. The reagents in this method tend to stain the test tubes. Same test tubes cannot be used since the stain would affect the absorbance reading. This method is also time sensitive. When more than one solution is tested, it is important to make sure every sample is incubated for the same amount of time for accurate comparison. A limiting factor in using Coomassie-based protein determination dyes stems from the significant variation in color yield observed across different proteins This limiting factor is notably evident in collagen-rich protein samples, like pancreatic extracts, where both the Lowry and Bradford methods tend to underestimate protein content. It is also inhibited by the presence of detergents, although this problem can be alleviated by the addition of cyclodextrins to the assay mixture. Much of the non-linearity stems from the equilibrium between two different forms of the dye which is perturbed by adding the protein. The Bradford assay linearizes by measuring the ratio of the absorbances, 595 over 450 nm. This modified Bradford assay is approximately 10 times more sensitive than the conventional one.
== Other animals == VWD can also affect dogs, pigs, and mice. Furthermore, cases have been reported in cats, horses, cattle, and rabbits. The causal mutation for VWD type 1 was identified in dogs of the breeds Doberman Pinscher, German Pinscher, Bernese Mountain Dog, Manchester Terrier, Kerry Blue Terrier, Cardigan Welsh Corgi, Poodle, Coton de Tulear, Drentse Patrijshond, Papillon, and Stabyhoun. Causal mutations for type 2 were identified in dogs of the breeds German Wirehaired Pointer, German Shorthaired Pointer, and Chinese Crested; and for type 3 in dogs of the breeds Kooikerhondje, Scottish Terrier and Shetland Sheepdog. In dogs affected by type 1 VWD, the causal mutation was the same across all breeds and the same mutation was also detected in some human VWD type 1 patients. In contrast, the mutations causing VWD type 3 in dogs are specific to each breed. Genetic screening is offered for known breeds. In pigs, the causal mutation for VWD type 3 has also been identified. It is a large duplication within the VWF gene and causes serious damage to the gene function, so that virtually no VWF protein is produced. The clinical picture in pigs is most similar to that in humans with VWD type 3. Therefore, those pigs are valuable models for clinical and pharmacological research. Mice affected by VWD type 3 were produced by genetic engineering to obtain a small sized model for the human disease. In these strains, the VWF gene has been knocked out. In animals of other species affected by VWD, the causal mutations have not yet been identified.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.